Golimumab News and Research

RSS
Merck reports strong bottom-line performance in second quarter

Merck reports strong bottom-line performance in second quarter

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck announces global sales of $27.4 billion for full-year 2009

Merck announces global sales of $27.4 billion for full-year 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough announces 2009 third quarter financial results

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Golimumab shows promise for rheumatoid arthritis

Golimumab shows promise for rheumatoid arthritis

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Trial of new biologic agent to treat psoriatic arthritis

Trial of new biologic agent to treat psoriatic arthritis